Appendix.
Subclass | Medication |
---|---|
Alkylating agents | Bendamustine |
Busulfan | |
Carmustine | |
Carmustine/polifeprosan | |
Chlorambucil | |
Cyclophosphamide | |
Dacarbazine | |
Estramustine | |
Ifosfamide | |
Lomustine | |
Mechlorethamine | |
Melphalan | |
Procarbazine | |
Streptozocin | |
Temozolomide | |
Thiotepa | |
Uracil mustard | |
Carboplatin | |
Cisplatin | |
Oxaliplatin | |
Antimetabolites | Methotrexate |
Pemetrexed | |
Cladribine | |
Clofarabine | |
Cytarabine | |
Fludarabine | |
Mercaptopurine | |
Nelarabine | |
Pentostatin | |
Thioguanine | |
Azacitidine | |
Capecitabine | |
Floxuridine | |
Fluorouracil | |
Gemcitabine | |
Hydroxyurea | |
Docetaxel (taxotere) | Docetaxel |
Other antimicrotubule agents | Paclitaxel |
Albumin-bound paclitaxel | |
Vinblastine | |
Vincristine | |
Vinorelbine | |
Ixabepilone | |
Topoisomerase-active agents | Irinotecan |
Topotecan | |
Daunorubicin | |
Doxorubicin | |
Pegylated liposomal | |
Doxorubicin | |
Epirubicin | |
Idarubicin | |
Mitoxantrone | |
Valrubicin | |
Etoposide | |
Teniposide | |
Antineoplastic antibiotics | Bleomycin |
Dactinomycin | |
Mitomycin C | |
Plicamycin | |
Biologically directed therapies | Alitretinoin |
Bexarotene | |
Bortezomib | |
Dasatinib | |
Erlotinib | |
Gefitinib | |
Imatinib | |
Lapatinib | |
Nilotinib | |
Sorafenib | |
Sunitinib | |
Temsirolimus | |
Tretinoin | |
Alemtuzumab | |
Bevacizumab | |
Cetuximab | |
Gemtuzumab | |
Ibritumomab | |
Panitumumab | |
Rituximab | |
Tositumomab | |
Trastuzumab | |
Immune therapies | Aldesleukin (IL-2) |
Interferon alfa-2a | |
Interferon alfa-2b | |
Lenalidomide | |
Thalidomide | |
Miscellaneous agents | Altretamine |
Arsenic trioxide | |
Asparaginase | |
Bcg vaccine | |
Decitabine | |
Denileukin | |
Levamisole | |
Mitotane | |
Pegaspargase | |
Porfimer | |
Strontium-89 | |
Vorinostat | |
Zoledronic acid (zometa) | Zoledronic acid |